Spotlight Presentation: Deciphering the Tumor Immune Microenvironment: A Novel Biomarker to Predict Immunotherapy Outcomes
24 Sep 2024
Sierra B
Immune Biomarkers
,
Translational Research
,
Clinical Development
,
Tumor Microenvironment (TME)
)
- The Tumor Immune Microenvironment (TIME) plays a crucial role in response to immunotherapies, the entirety of the TIME is not captured by today’s standard biomarkers.
- DetermaIO is a TIME classifier that measures the interplay of the immune system, stromal interactions, and tumor biology to identify patients poised to respond to immunotherapy.
- DetermaIO may fill the current unmet need to identify selective benefit to ICIs, capable of enriching clinical trials, driving personalized medicine, and improve outcomes for patients.
Industry Expert
